Antipyretic Effect of Parenteral Paracetamol (Propacetamol) in Pediatric Oncologic Patients: A Randomized Trial

The antipyretic efficacy of propacetamol, an intravenous prodrug of paracetamol, was evaluated in two pediatric prospective randomized studies. In the first, we compared one standard intravenous dose of propacetamol (30 mg/kg) to one standard intravenous dose of acetyl-salicylic acid (ASA, 15 mg/kg)...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric hematology and oncology 1997, Vol.14 (1), p.51-57
Main Authors: Reymond, Didier, Birrer, Peter, Liithy, Anette Ridolfi, Rimensberger, Peter C., Beck, Maya Nenadov
Format: Article
Language:English
Subjects:
acetaminophen
Acetaminophen - adverse effects
Acetaminophen - therapeutic use
Analgesics, Non-Narcotic - adverse effects
Analgesics, Non-Narcotic - therapeutic use
Aspirin - adverse effects
Aspirin - therapeutic use
Bacterial Infections - complications
Biological and medical sciences
Child
Child, Preschool
fever
Fever - drug therapy
Fever - etiology
Humans
Infusions, Intravenous
Medical sciences
Miscellaneous
Neoplasms - complications
neutropenia
Neutropenia - drug therapy
Neutropenia - etiology
paracetamol
Pharmacology. Drug treatments
prodrug
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antipyretic efficacy of propacetamol, an intravenous prodrug of paracetamol, was evaluated in two pediatric prospective randomized studies. In the first, we compared one standard intravenous dose of propacetamol (30 mg/kg) to one standard intravenous dose of acetyl-salicylic acid (ASA, 15 mg/kg) in 10 nononcologic patients with bacterial illnesses. In the second study, we compared two intravenous doses of propacetamol (30 mg/kg versus 15 mg/kg) in 24 oncologic patients with fever and neutropenia. No statistically significant differences in antipyretic efficacy were found between standard doses of propacetamol and ASA; even when half-doses of propacetamol (15 mg/kg) were used, good antipyretic efficacy was observed, which was not statistically different from that observed with the full dose. The use of propacetamol seems promising for patients (such as oncologic patients) who cannot receive enteral paracetamol formulas.
ISSN:0888-0018
1521-0669
DOI:10.3109/08880019709030884